Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

NASH Screening in Diabetes

Source: Hot Topics in NASH: Current Controversies and New Developments in Fatty Liver Disease
Hear Brent A. Neuschwander-Tetri, MD, explore NASH screening and the interplay among NAFLD, metabolic syndrome, CV risk, and diabetes risk.
Brent A. Neuschwander-Tetri, MD
Released: July 7, 2020

Hear Brent A. Neuschwander-Tetri, MD, explore NASH screening and the interplay among NAFLD, metabolic syndrome, CV risk, and diabetes risk, including:

  • Should We Screen for NASH?
    • Role of obesity and type 2 diabetes mellitus
  • Cardiovascular Risk in NAFLD/NASH
  • How to Evaluate for NAFLD/NASH
    • Biomarkers
    • Imaging
    • When/whom to biopsy?
  • Management in Multidisciplinary Settings

Download the slides from this podcast at: https://www.clinicaloptions.com/internal-medicine/programs/2019-nash-hot-topics/screening-for-nash-in-patients-with-diabetes/slideset

See more NASH topics at: https://www.clinicaloptions.com/internal-medicine/programs/2019-nash-hot-topics

Information on this Educational Activity

Faculty

Brent A. Neuschwander-Tetri, MD

Professor of Internal Medicine
Associate Chair for Clinical Trials
Saint Louis University School of Medicine
St Louis, Missouri

Brent A. Neuschwander-Tetri, MD, has disclosed that he has received consulting fees from Allergan, Allysta, Arrowhead, ARTham, Axcella, Blade, Boehringer Ingelheim, Bristol-Myers Squibb, Coherus, Consynance, CymaBay, Durect, Enanta, Ferring, Fortress, Gelesis, Genfit, Gilead Sciences, HighTide, HistoIndex, Intercept, Lipocine, Llama, Madrigal, MedImmune, Merck, Metacrine, Mundipharma, NGM, pH-Pharma, Prometheus, and Siemens and funds for research support paid to Saint Louis University from Allergan, Bristol-Myers Squibb, Cirius, CymaBay, Enanta, Galectin, Genfit, Gilead Sciences, Intercept, Madrigal, NGM, and Prometheus.

Staff

Zachary Schwartz, MSc

Scientific Director

Zachary Schwartz, MSc, ELS, has no relevant conflicts of interest to report.

Program Medium

This program has been made available online.

Acknowledgements

Provided by the American Gastroenterology Association.
Contact Info

American Gastroenterological Association (AGA)
4930 Del Ray Avenue
Bethesda, MD 20814
Phone: (301) 654-2055
Fax: (301) 654-5920
Email: member@gastro.org

Produced in collaboration with
Endocrine Society Logo
Supported by educational grants from
Allergan
Gilead Sciences
Intercept Pharmaceuticals, Inc.

Related Content

Hear Philip Newsome, PhD FRCPE, discuss available approaches to managing NASH: lifestyle, vitamin E, compounds that target insulin resistance from CCO

Philip N. Newsome, PhD, FRCPE Released: July 2, 2020

Hear Philip Newsome, PhD FRCPE, discuss the agents in late-phase clinical trials and their potential use in treatment of NASH and fibrosis from CCO

Philip N. Newsome, PhD, FRCPE Released: July 1, 2020

Expert commentary on prevention and emerging treatment strategies for the COVID-19 pandemic from CCO

Daniel R. Kuritzkes, MD Released: March 19, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue